Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of “Buy” by Brokerages

Monopar Therapeutics Inc. (NASDAQ:MNPR) has earned a consensus recommendation of “Buy” from the thirteen brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $106.20.

A number of analysts have issued reports on MNPR shares. Chardan Capital boosted their target price on Monopar Therapeutics from $85.00 to $100.00 and gave the company a “buy” rating in a research report on Sunday, November 9th. Raymond James Financial cut Monopar Therapeutics from a “strong-buy” rating to an “outperform” rating and dropped their price objective for the company from $142.00 to $123.00 in a research note on Friday, November 14th. HC Wainwright set a $105.00 target price on Monopar Therapeutics and gave the stock a “buy” rating in a research note on Monday, September 29th. Wall Street Zen upgraded Monopar Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday. Finally, Leerink Partnrs upgraded shares of Monopar Therapeutics to a “strong-buy” rating in a research note on Monday, November 10th.

Insiders Place Their Bets

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 550,229 shares of the stock in a transaction that occurred on Wednesday, September 24th. The shares were sold at an average price of $63.61, for a total transaction of $35,000,066.69. Following the sale, the insider directly owned 272,026 shares in the company, valued at $17,303,573.86. This represents a 66.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 20.50% of the stock is currently owned by insiders.

Institutional Trading of Monopar Therapeutics

Several hedge funds have recently modified their holdings of MNPR. Wellington Management Group LLP acquired a new position in Monopar Therapeutics during the 3rd quarter worth $18,904,000. Deerfield Management Company L.P. purchased a new position in shares of Monopar Therapeutics in the 3rd quarter valued at about $13,048,000. TCG Crossover Management LLC acquired a new position in shares of Monopar Therapeutics during the third quarter worth about $12,496,000. Vanguard Group Inc. increased its stake in shares of Monopar Therapeutics by 140.7% during the third quarter. Vanguard Group Inc. now owns 208,218 shares of the company’s stock worth $17,005,000 after buying an additional 121,729 shares during the period. Finally, Vivo Capital LLC acquired a new stake in Monopar Therapeutics in the third quarter valued at approximately $7,391,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Monopar Therapeutics Price Performance

Shares of MNPR stock opened at $74.61 on Monday. Monopar Therapeutics has a 1-year low of $21.00 and a 1-year high of $105.00. The firm has a market cap of $498.39 million, a PE ratio of -21.69 and a beta of 1.46. The company has a 50-day moving average of $84.16 and a two-hundred day moving average of $57.73.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). Sell-side analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.